JPMorgan Upgrades Momenta Pharmaceuticals (MNTA) to Overweight

January 14, 2020 4:23 PM EST Send to a Friend
JPMorgan analyst Eric Joseph upgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Neutral to Overweight with a price target of $30.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login